Insider · CIK 0001989488
Caroline Loew
Files at MURA (Mural Oncology plc). First filing Jul 8, 2024, latest Jul 9, 2025.
In brief
Caroline Loew files SEC Form 4 as CEO and director at MURA (Mural Oncology plc). Since Jul 8, 2024, Caroline Loew has reported 0 open-market buys worth $0 and 3 open-market sells worth $76k, the latest filed on Jul 9, 2025.
A track record needs three past buys with six months of prices behind them; Caroline Loew has 0, so none is measured yet.
The newest scored trade: sold $30k of MURA on Jul 7, 2025, filed Jul 9, 2025, scored 18 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Mural Oncology plc | $30k 12,531 shares | -4% | - | |
| 13Weak | Mural Oncology plc | $9,394 2,763 shares | -1% | - | |
| 19Weak | Mural Oncology plc | $36k 12,531 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 9, 2025 | MURA Mural Oncology plc | 12,513 0.07% of outstanding | $30k | Jul 7, 2025 | none |
| Mar 5, 2025 | MURA Mural Oncology plc | 4,313 0.03% of outstanding | $14k | Mar 4, 2025 | $9,395 |
| Jul 8, 2024 | MURA Mural Oncology plc | 12,531 0.07% of outstanding | $36k | Jul 8, 2024 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Ordinary Shares | -293,059 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Stock Option (right to buy)derivative | -379,690 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Stock Option (right to buy)derivative | -90,025 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Stock Option (right to buy)derivative | -134,225 | - | - | 0 | Dec 5, 2025 |
| Jul 7, 2025 | MURA Mural Oncology plc | SOpen-market sale Ordinary Shares10b5-1 | -12,531 | $2.43 | $30k | 293,059 | Jul 9, 2025 |
| Dec 17, 2024 | MURA Mural Oncology plc | SOpen-market sale Ordinary Shares10b5-1 | -2,763 | $3.40 | $9,394 | 237,628 | Dec 18, 2024 |
| Jul 8, 2024 | MURA Mural Oncology plc | SOpen-market sale Ordinary Shares10b5-1 | -12,531 | $2.91 | $36k | 240,391 | Jul 8, 2024 |
| Dec 14, 2023 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +379,690 | - | - | 379,690 | Apr 11, 2024 |
| Mar 1, 2024 | MURA Mural Oncology plc | AGrant or award Ordinary Shares | +48,475 | $0.00 | $0 | 252,922 | Mar 4, 2024 |
| Mar 1, 2024 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +90,025 | $0.00 | $0 | 90,025 | Mar 4, 2024 |
| Dec 14, 2023 | MURA Mural Oncology plc | AGrant or award Ordinary Shares | +167,276 | $0.00 | $0 | 167,276 | Dec 18, 2023 |
| Dec 14, 2023 | MURA Mural Oncology plc | AGrant or award Ordinary Shares | +37,171 | $0.00 | $0 | 37,171 | Dec 18, 2023 |
| Dec 14, 2023 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +379,690 | - | - | 379,690 | Dec 18, 2023 |
Questions about Caroline Loew
Answered from the filings on this page, as of the latest one.
Is Caroline Loew buying or selling?
Not in the last 12 months. Caroline Loew's latest open-market trade on SEC Form 4 was sold $30k of MURA on Jul 7, 2025.
How did Caroline Loew's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Caroline Loew has 0.
Where does Caroline Loew file Form 4?
Caroline Loew has filed Form 4 at MURA (Mural Oncology plc) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.